Ironwood Pharmaceuticals, Inc. (IRWD)
USD 0.77
(7.66%)
USD 0.77
(7.66%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -924.86 Million USD | -18.95% |
| 2022 | 261.43 Million USD | 11.55% |
| 2021 | 233.33 Million USD | 45.72% |
| 2020 | 141.9 Million USD | 32.74% |
| 2019 | 101.12 Million USD | 228.23% |
| 2018 | -144.45 Million USD | 8.37% |
| 2017 | -33.11 Million USD | -151.9% |
| 2016 | -31.29 Million USD | 51.82% |
| 2015 | -99.94 Million USD | 50.14% |
| 2014 | -156.12 Million USD | 32.79% |
| 2013 | -240.08 Million USD | -246.34% |
| 2012 | -61.24 Million USD | -30.66% |
| 2011 | -54.78 Million USD | 10.44% |
| 2010 | -52.99 Million USD | 7.58% |
| 2009 | -67.27 Million USD | -32.05% |
| 2008 | -51.84 Million USD | 1.58% |
| 2007 | -51.16 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 11.97 Million USD | -67.68% |
| 2024 Q2 | 27.55 Million USD | 111.4% |
| 2023 Q3 | 46.45 Million USD | 104.38% |
| 2023 Q4 | 44.92 Million USD | -3.3% |
| 2023 Q1 | 67.36 Million USD | -8.73% |
| 2023 Q2 | -1.06 Billion USD | -1675.46% |
| 2023 FY | - USD | -18.95% |
| 2022 Q2 | 56.51 Million USD | -2.38% |
| 2022 Q3 | 71.24 Million USD | 26.06% |
| 2022 Q4 | 73.8 Million USD | 3.6% |
| 2022 FY | - USD | 11.55% |
| 2022 Q1 | 57.89 Million USD | 1.98% |
| 2021 Q4 | 56.77 Million USD | -12.94% |
| 2021 FY | - USD | 45.72% |
| 2021 Q2 | 64.97 Million USD | 41.5% |
| 2021 Q1 | 45.91 Million USD | -30.17% |
| 2021 Q3 | 65.2 Million USD | 0.36% |
| 2020 FY | - USD | 32.74% |
| 2020 Q3 | 48.52 Million USD | 45.87% |
| 2020 Q2 | 33.26 Million USD | 131.57% |
| 2020 Q1 | 14.36 Million USD | -71.51% |
| 2020 Q4 | 65.75 Million USD | 35.49% |
| 2019 Q1 | -49.06 Million USD | -823.9% |
| 2019 Q3 | 66.32 Million USD | 231.58% |
| 2019 Q4 | 50.43 Million USD | -23.96% |
| 2019 FY | - USD | 228.23% |
| 2019 Q2 | 20 Million USD | 140.77% |
| 2018 Q3 | -38.84 Million USD | -28.4% |
| 2018 FY | - USD | 8.37% |
| 2018 Q1 | -31.88 Million USD | -145.46% |
| 2018 Q2 | -30.25 Million USD | 5.1% |
| 2018 Q4 | 6.77 Million USD | 117.45% |
| 2017 Q4 | -12.98 Million USD | 17.43% |
| 2017 Q3 | -15.72 Million USD | 49.48% |
| 2017 FY | - USD | -151.9% |
| 2017 Q2 | -31.13 Million USD | 9.4% |
| 2017 Q1 | -34.36 Million USD | -2245.8% |
| 2016 FY | - USD | 51.82% |
| 2016 Q4 | -1.46 Million USD | 91.07% |
| 2016 Q3 | -16.4 Million USD | -15.14% |
| 2016 Q2 | -14.25 Million USD | -1412.15% |
| 2016 Q1 | 1.08 Million USD | 118.64% |
| 2015 Q4 | -5.82 Million USD | 65.1% |
| 2015 Q2 | -42 Million USD | -49.67% |
| 2015 Q3 | -16.69 Million USD | 60.25% |
| 2015 Q1 | -28.06 Million USD | 15.27% |
| 2015 FY | - USD | 50.14% |
| 2014 Q1 | -44.38 Million USD | 5.03% |
| 2014 Q3 | -36.73 Million USD | 33.35% |
| 2014 Q4 | -33.12 Million USD | 9.84% |
| 2014 FY | - USD | 32.79% |
| 2014 Q2 | -55.11 Million USD | -24.18% |
| 2013 FY | - USD | -246.34% |
| 2013 Q2 | -59.88 Million USD | 30.37% |
| 2013 Q3 | -56.55 Million USD | 5.56% |
| 2013 Q4 | -46.73 Million USD | 17.35% |
| 2013 Q1 | -85.99 Million USD | -95.88% |
| 2012 Q1 | -35.67 Million USD | -732.66% |
| 2012 FY | - USD | -30.66% |
| 2012 Q3 | 47.58 Million USD | 216.43% |
| 2012 Q2 | -40.86 Million USD | -14.56% |
| 2012 Q4 | -43.9 Million USD | -192.26% |
| 2011 Q2 | -16.04 Million USD | 14.1% |
| 2011 Q4 | -4.28 Million USD | 77.72% |
| 2011 FY | - USD | 10.44% |
| 2011 Q3 | -19.22 Million USD | -19.8% |
| 2011 Q1 | -18.68 Million USD | -74.44% |
| 2010 Q4 | -10.71 Million USD | 26.33% |
| 2010 FY | - USD | 7.58% |
| 2010 Q2 | -15.81 Million USD | 2.38% |
| 2010 Q1 | -16.2 Million USD | 28.73% |
| 2010 Q3 | -14.53 Million USD | 8.09% |
| 2009 FY | - USD | -32.05% |
| 2009 Q1 | -17.53 Million USD | -14.03% |
| 2009 Q2 | -16.93 Million USD | 3.4% |
| 2009 Q3 | -6.95 Million USD | 58.94% |
| 2009 Q4 | -22.73 Million USD | -226.87% |
| 2008 Q4 | -15.37 Million USD | 0.0% |
| 2008 FY | - USD | 1.58% |
| 2007 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Aquestive Therapeutics, Inc. | 1.18 Million USD | 78345.77% |
| Collegium Pharmaceutical, Inc. | 308.32 Million USD | 399.961% |
| Journey Medical Corporation | 1.92 Million USD | 48244.977% |
| Dynavax Technologies Corporation | 9.66 Million USD | 9668.229% |
| Esperion Therapeutics, Inc. | -150.1 Million USD | -516.133% |
| Intra-Cellular Therapies, Inc. | -158.85 Million USD | -482.214% |
| Pacira BioSciences, Inc. | 162.89 Million USD | 667.761% |
| PainReform Ltd. | -9.56 Million USD | -9565.221% |
| Petros Pharmaceuticals, Inc. | -4.21 Million USD | -21858.531% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | -24083.157% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | -24083.157% |
| SCYNEXIS, Inc. | 73.47 Million USD | 1358.679% |
| Silver Spike Investment Corp. | 7.34 Million USD | 12700.152% |
| China SXT Pharmaceuticals, Inc. | -2.35 Million USD | -39239.05% |
| Alpha Teknova, Inc. | -25.53 Million USD | -3521.383% |
| Alvotech | -484.86 Million USD | -90.748% |
| ANI Pharmaceuticals, Inc. | 109.32 Million USD | 946.016% |
| Bright Green Corporation | - USD | Infinity% |
| Embecta Corp. | 245.4 Million USD | 476.881% |
| Safety Shot Inc | -12.18 Million USD | -7490.078% |
| Procaps Group, S.A. | 104.02 Million USD | 989.062% |
| Cosmos Health Inc. | -17.06 Million USD | -5320.678% |
| Theratechnologies Inc. | -10.31 Million USD | -8868.129% |
| Harrow Health, Inc. | 9.72 Million USD | 9612.136% |
| Sonoma Pharmaceuticals, Inc. | -4.52 Million USD | -20339.006% |
| Biofrontera Inc. | -18.45 Million USD | -4912.003% |
| DURECT Corporation | -24.68 Million USD | -3646.82% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | 1041.223% |
| Cronos Group Inc. | -72.14 Million USD | -1181.882% |
| OptiNose, Inc. | -15.55 Million USD | -5846.538% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | -2463.231% |
| RedHill Biopharma Ltd. | 26.26 Million USD | 3621.13% |
| Organogenesis Holdings Inc. | 36.03 Million USD | 2666.859% |
| Guardion Health Sciences, Inc. | -3.92 Million USD | -23479.335% |
| Cumberland Pharmaceuticals Inc. | -710.85 Thousand USD | -130006.914% |
| Radius Health, Inc. | 38.31 Million USD | 2514.161% |
| Universe Pharmaceuticals INC | -3.21 Million USD | -28666.568% |
| ProPhase Labs, Inc. | -14.82 Million USD | -6137.708% |
| Phibro Animal Health Corporation | 84.6 Million USD | 1193.131% |
| Procaps Group S.A. | 104.02 Million USD | 989.062% |
| TherapeuticsMD, Inc. | -8.4 Million USD | -10908.987% |
| Viatris Inc. | 3.51 Billion USD | 126.301% |
| Rockwell Medical, Inc. | -4.69 Million USD | -19603.132% |
| Aytu BioPharma, Inc. | -1.01 Million USD | -91289.822% |
| SIGA Technologies, Inc. | 84.15 Million USD | 1198.944% |
| Tilray Brands, Inc. | -72.84 Million USD | -1169.669% |
| Lifecore Biomedical, Inc. | 812 Thousand USD | 113999.63% |
| Shineco, Inc. | -26.55 Million USD | -3382.971% |
| PetIQ, Inc. | 81.48 Million USD | 1234.999% |
| Regencell Bioscience Holdings Limited | -3.61 Million USD | -25465.509% |
| Incannex Healthcare Limited | -18.5 Million USD | -4898.19% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | 322.27% |
| Alimera Sciences, Inc. | 7.27 Million USD | 12811.174% |
| Assertio Holdings, Inc. | -222.44 Million USD | -315.769% |
| Shuttle Pharmaceuticals Holdings, Inc. | -3.99 Million USD | -23075.804% |
| Clever Leaves Holdings Inc. | -16.8 Million USD | -5403.838% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | -4517.219% |
| Avadel Pharmaceuticals plc | -149.12 Million USD | -520.194% |
| Hempacco Co., Inc. | -12.77 Million USD | -7140.629% |
| Talphera, Inc. | -9.84 Million USD | -9297.125% |
| Alvotech | -484.86 Million USD | -90.748% |
| Eagle Pharmaceuticals, Inc. | 77.5 Million USD | 1293.343% |
| Lantheus Holdings, Inc. | 491 Million USD | 288.362% |
| Currenc Group, Inc. | -1.9 Million USD | -48562.404% |
| Kamada Ltd. | 21.53 Million USD | 4394.906% |
| Indivior PLC | 66 Million USD | 1501.311% |
| Evoke Pharma, Inc. | -7.29 Million USD | -12582.77% |
| Flora Growth Corp. | -45.87 Million USD | -1916.274% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | -4517.219% |
| Evolus, Inc. | -41.81 Million USD | -2112.066% |
| HUTCHMED (China) Limited | 25.52 Million USD | 3722.943% |
| Amphastar Pharmaceuticals, Inc. | 241.46 Million USD | 483.024% |
| Akanda Corp. | -27.73 Million USD | -3234.567% |